Wolchok, Jedd D.

Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications

Shia, J., Schultz, N., Kuk, D., Vakiani, E., Middha, S., Segal, N. H., Hechtman, J. F., Berger, M. F., Stadler, Z. K., Weiser, M. R., et al. (2017) · Modern Pathology

Genetic factors in colorectal cancerCancer Genomics and Diagnostics

Cited by 105

Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer

Choi, H., Deng, J., Li, S., Silk, T., Dong, L., Brea, E. J., Houghton, S., Redmond, D., Zhong, H., Boiarsky, J., et al. (2019) · Cell Reports

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 72

Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma

Balachandran, V. P., Rojas, L. A., Sethna, Z., Soares, K., Derhovanessian, E., Mueller, F., Yadav, M., Basturk, O., Gonen, M., Wei, A. C.-C., et al. (2022) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchImmunotherapy and Immune Responses

Cited by 33

Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.

Schindler, K., Harmankaya, K., Postow, M. A., Frantal, S., Bello, D., Ariyan, C. E., Michielin, O. A., Hoeller, C., Pehamberger, H., & Wolchok, J. D. (2013) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease Prognosis

Cited by 30

Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies

Dobrin, A., Lindenbergh, P. L., Shi, Y., Perica, K., Xie, H., Jain, N., Chow, A., Wolchok, J. D., Merghoub, T., Sadelain, M., et al. (2024) · Nature Cancer

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 23

Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

Grob, J.-J., Schadendorf, D., Wagstaff, J., Márquez-Rodas, I., Lebbé, C., Ascierto, P. A., Hodi, F. S., Grossmann, K., Hassel, J. C., Walker, D., et al. (2017) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 8